Effects of venlafaxine treatment on clozapine plasma levels in schizophrenic patients

Neuropsychobiology

Volumn 51, Issue 4, 2005, Pages 173-176

  Repo Tiihonen, Eila ^a   Eloranta, Anne ^a   Hallikainen, Tero ^a   Tiihonen, Jari ^a,b,c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Clozapine; Venlafaxine

Indexed keywords

CHLORDIAZEPOXIDE; CISAPRIDE; CLOMETHIAZOLE; CLONAZEPAM; CLOZAPINE; HYDROXYZINE; METHYLPREDNISOLONE; OXAZEPAM; PANTOPRAZOLE; SCOPOLAMINE; TEMAZEPAM; VALPROIC ACID; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DRUG BLOOD LEVEL; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLOZAPINE; CYCLOHEXANOLS; DEPRESSION; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA;

EID: 22144481650     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085591     Document Type: Article

References (21)

1. Whitehead C, Moss S, Cardno A, Lewis G: Antidepressants for people with both schizophrenia and depression. Cochrane Database Syst Rev 2002;2:CD002305.
2. Baynes D, Mulholland C, Cooper SJ, Montgomery RC, MacFlynn G, Lynch G, Kelly C, King DJ: Depressive symptoms in stable chronic schizophrenia: Prevalence and relationship to psychopathology and treatment. Schizophr Res 2000;45:47-56.
3. Lancon C, Auquier P, Reine G, Bernard D, Addinton D: Relationships between depression and psychotic symptoms of schizophrenia during an acute episode and stable period. Schizophr Res 2001;47:135-140.
4. Wetzel H, Anghelescu I, Szegedi A, Wiesner J, Weigmann H, Härtter S, Hiemke C: Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: Differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 1998;18:2-9.
5. Wagstaff AJ, Bryson HM: Clozapine: A review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs 1995;4:370-400.
6. Azorin JM, Speigel R, Remington G, Vanelle JM, Pere JJ, Giguere M, Bourdeix I: A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry 2001;158:1305-1313.
7. Jerling M, Lindström L, Bondesson U, Bertilsson L: Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: Evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-374.
8. Centorrino F, Baldessarini RJ, Frankenburg FR, Kando J, Volpicelli SA, Flood JG: Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 1996;153:820-822.
9. Nemeroff CB, DeVane CL, Pollock BG: Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-320.
10. Thase ME: Antidepressants options: Venlafaxine in perspective. J Clin Psychopharmacol 1996;16(suppl 2):10S-17S.
11. Rotzinger S, Bourin M, Akimoto Y, Coutts RT, Baker GB: Metabolism of some 'second'-and 'fourth' generation antidepressants: Iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine. Cell Mol Neurobiol 1999;19:427-442.
12. Otton SV, Ball SE, Cheung SW, Inba T, Rudolph RL, Sellers EM: Venlafaxine oxidation in vitro is catalysed by CYP 2D6. Br J Clin Pharmacol 1996;41:149-156.
13. Syvälahti E: Venlafaksiini - uusi masennuslääke (in Finnish). Suomen Lääkärilehti 1996;51:36-37.
14. Owen JR, Nemeroff CB: New antidepressants and the cytochrome P450 system: Focus on venlafaxine, nefazodone and mirtazapine. Depress Anxiety 1998;7(suppl 1):24-32.
15. Åkerman KK: Analysis of clozapine and norclozapine by high-performance liquid chromatography. J Chromatogr B 1997;696:253-259.
16. World Health Organization: The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, WHO, 1992.
17. Ereshefsky L: Drug-drug interactions involving antidepressants: Focus on venlafaxine. J Clin Pharmacol 1996;16(suppl 2):37S-50S.
18. Ereshefsky L, Riesenman C, Lam YW: Antidepressant drug interactions and the cytochrome P450 system: The role of cytochrome P450 2D6. Clin Pharmacokinet 1995;29(suppl 1):10-19.
19. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine: Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999;37:177-193.
20. Ereshefsky L: Pharmacokinetics and drug interactions: Update for new antipsychotics. J Clin Psychiatry 1996;57(suppl 11):12-25.
21. Centorrino F, Baldessarini RJ, Kando J, Frankenburg FR, Volpicelli SA, Poupolo PR, Flood JG: Serum concentrations of clozapine and its major metabolites: Effects of cotreatment with fluoxetine or valproate. Am J Psychiatry 1994;151:123-125.